Phaseline

Targets › FIG4

FIG4 (Polyphosphoinositide phosphatase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2032.

Dual specificity phosphatase component of the PI(3,5)P2 regulatory complex which regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Catalyzes the dephosphorylation of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) to form phosphatidylinositol 3-phosphate. (UniProt, Q92562)

Open in Phaseline: the race on FIG4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Elpida Therapeutics SPCELP-02
AAV9-based gene therapy expressing FIG4
FIG4Phase 1Charcot-Marie-Tooth Disease Type 4JDec 2032

Conditions

Charcot-Marie-Tooth Disease Type 4J (1)

Modalities

other (1)

Companies

Elpida Therapeutics SPC (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.